testosterone undecanoate IM
Selected indexed studies
- Male idiopathic oligoasthenoteratozoospermia. (Asian J Androl, 2006) [PMID:16491265]
- Serum testosterone and bioavailable testosterone correlate with age and body size in hypogonadal men treated with testosterone undecanoate (1000 mg IM--Nebido). (Clin Endocrinol (Oxf), 2008) [PMID:18394021]
- Pharmacokinetics and Acceptability of Subcutaneous Injection of Testosterone Undecanoate. (J Endocr Soc, 2019) [PMID:31384715]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Occurrence of pulmonary oil microembolism (POME) with intramuscular testosterone undecanoate injection: literature review. (2023) pubmed
- Male idiopathic oligoasthenoteratozoospermia. (2006) pubmed
- Serum testosterone and bioavailable testosterone correlate with age and body size in hypogonadal men treated with testosterone undecanoate (1000 mg IM--Nebido). (2008) pubmed
- Pharmacokinetics and Acceptability of Subcutaneous Injection of Testosterone Undecanoate. (2019) pubmed
- Testosterone undecanoate: a useful tool for testosterone administration in rats. (2003) pubmed
- Long-term administration of testosterone undecanoate every 3 months for testosterone supplementation in female-to-male transsexuals. (2007) pubmed
- Testosterone undecanoate and testosterone enanthate injections are both effective and safe in transmen over 5 years of administration. (2018) pubmed
- Effects of Long-Acting Testosterone Undecanoate on Behavioral Parameters and Na + , K(+)-ATPase mRNA Expression in Mice with Alzheimer`s Disease. (2021) pubmed
- Pharmacological treatment for pubertal progression in boys with delayed or slow progression of puberty: A small-scale randomized study with testosterone enanthate and testosterone undecanoate treatment. (2023) pubmed
- Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism. (2004) pubmed